Skip to main content

Egrifta FDA Approval History

FDA Approved: Yes (First approved November 10, 2010)
Brand name: Egrifta
Generic name: tesamorelin
Dosage form: Injection
Company: Theratechnologies
Treatment for: Reduction of Excess Abdominal Fat in HIV-Infected Patients with Lipodystrophy

Egrifta (tesamorelin) is a synthetic analogue of growth hormone releasing factor (GRF) for the treatment of excess abdominal fat in HIV patients with lipodystrophy.

Development timeline for Egrifta

DateArticle
Nov 11, 2010Approval FDA Approves Egrifta (tesamorelin for injection): First and Only Treatment for the Reduction of Excess Abdominal Fat in HIV-infected Patients with Lipodystrophy
Jul 22, 2010Theratechnologies: Update on timeline for FDA Action Date
Jun  7, 2010Theratechnologies announces positive vote by FDA Advisory Committee for tesamorelin
Mar 22, 2010FDA Confirms Date for Advisory Committee Review of the Tesamorelin New Drug Application
Feb 25, 2010Theratechnologies Announces a Tentative New Date for the FDA Advisory Committee Review of the tesamorelin New Drug Application
Nov  5, 2009Theratechnologies' NDA for Tesamorelin to be Reviewed by an FDA Advisory Committee
Aug 12, 2009U.S. Food And Drug Administration Has Accepted To File Theratechnologies' New Drug Application for tesamorelin
Jun  3, 2009Theratechnologies Files a New Drug Application for Tesamorelin With the US Food and Drug Administration

See also

Egrifta (tesamorelin) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer